Adopting the Evolving Management of HR+/HER2-mBC into Practice
By Annenberg Center for Health Sciences
Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, includi... more